ENGI 002
Alternative Names: ENGI-002; ENGI-002 specTRLatest Information Update: 23 May 2024
At a glance
- Originator Engimmune Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Apr 2024 Preclinical trials in Solid tumours in Switzerland (Parenteral) prior to April 2024 (Engimmune Therapeutics pipeline, April 2024)
- 30 Apr 2024 Engimmune Therapeutics plans a phase I clinical trial for Solid tumours in 2025 (Engimmune Therapeutics pipeline, April 2024)